Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | HMGCR | P04035 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CES2 | O00748 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17933420 | 0.94 | ALDH1A1 (0.42) | ALDH1A1TDP1TRPA1HMGCRCHRM1 | |
| SCHEMBL16587771 | 0.90 | HMGCR (0.44) | ALDH1A1TDP1HMGCRCHRM1TBXA2R | |
| SCHEMBL4783944 | 0.90 | HMGCR (0.44) | ALDH1A1TDP1HMGCRCHRM1TBXA2R | |
| SCHEMBL4953125 | 0.85 | LMNA (0.42) | ALDH1A1TDP1ADRA1ATSHRCES2 | |
| SCHEMBL4743859 | 0.84 | MGAM (0.44) | ALDH1A1TDP1TSHR | |
| SCHEMBL12141327 | 0.83 | ALDH1A1 (0.33) | ALDH1A1TDP1TSHRSMN1; SMN2 | |
| SCHEMBL21095787 | 0.81 | ALDH1A1 (0.32) | ALDH1A1TDP1 | |
| SCHEMBL14886607 | 0.79 | ALDH1A1 (0.31) | ALDH1A1TDP1 | |
| SCHEMBL20608207 | 0.78 | HSD11B1 (0.37) | ALDH1A1 | |
| SCHEMBL20608208 | 0.78 | HSD11B1 (0.37) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150093692-A1 | PATTERN FORMING METHOD, ACTINIC RAY-SENSITIVE OR RADIATION-SENSITIVE RESIN COMPOSITION AND RESIST FILM USED THEREFOR, AND ELECTRONIC DEVICE MANUFACTURING METHOD AND ELECTRONIC DEVICE USING THE SAMEDEVICE MANUFACTURING METHOD AND ELECTRONIC DEVICE USING THE SAME | FUJIFILM CORPORATION (JP) | 2015-04-02 | — | — | US | disclosed |
| EP-2518079-A2 | HCV/HIV inhibitors and their uses | Novartis AG (CH) | 2012-10-31 | — | — | EP | disclosed |
| US-20120101098-A1 | 3,28-DISUBSTITUTED BETULINIC ACID DERIVATIVES AS ANTI-HIV AGENTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-04-26 | — | — | US | disclosed |
| WO-2007133865-A2 | HCV/HIV INHIBITORS AN THEIR USES | NOVARTIS AG (CH) | 2007-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101098-A1 | 3,28-DISUBSTITUTED BETULINIC ACID DERIVATIVES AS ANTI-HIV AGENTS | BET1, CD4, PGGT1B | ALDH1A1 2309/4885TDP1 1989/4885TRPA1 4803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.